Skip to main content
ChemoPrescribe LLC.
  • HOME
  • ABOUT
  • SIGN IN
  • SIGN UP

Other Pages – Top Ad

Oncoprescribe-SI

Advertisement

⟰ 🠈

BRUKINSA® (Zanubrutinib)

February 18, 2022February 18, 2022 RR FDA Approvals
Waldenström’s Macroglobulinemia

The FDA on August 31, 2021, approved BRUKINSA® for adult patients with Waldenström’s Macroglobulinemia (WM). BRUKINSA® is a product of BeiGene.

Related Posts:

  • BRUKINSA® (Zanubrutinib)
  • BRUKINSA® (Zanubrutinib)
  • BRUKINSA® (Zanubrutinib)
  • BRUKINSA® Superior to IMBRUVICA® in…
  • BRUKINSA® Superior to IMBRUVICA® in…
  • BRUKINSA® for First Line Treatment of Chronic…

Post navigation

Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants
BRUKINSA® (Zanubrutinib)

Other Pages – Bottom Ad

hem-onc-updates

Advertisement

Subscribe

FREE SUBSCRIPTION
  • ABOUT
  • PRIVACY
  • TERMS
  • DISCLAIMER
  • CONTACT
ChemoPrescribe LLC. All Rights Reserved

Leaving ChemoPrescribe

You are now leaving ChemoPrescribe website.

To return to the website, click on the back arrow on your browser.